Carregant...
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
The last several years have witnessed exciting progress in the development of immunotherapy for the treatment of cancer. This has been due in great part to the development of so-called checkpoint blockade. That is, antibodies that block inhibitory receptors such as CTLA-4 and PD-1 and thus unleash a...
Guardat en:
| Publicat a: | Comput Struct Biotechnol J |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Research Network of Computational and Structural Biotechnology
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4415113/ https://ncbi.nlm.nih.gov/pubmed/25941561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.csbj.2015.03.008 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|